NEW YORK (GenomeWeb News) — WaferGen Biosystems said today that it has completed a private placement of common stock, Series 1 convertible preferred stock, and warrants to purchase shares of common stock to accredited investors, netting just over $15 million.

WaferGen said that it intends to use the net proceeds for general corporate and working capital purposes, including sales of its SmartChip TE for next-generation sequencing target enrichment and SmartChip MyDesign for high-throughput quantitative PCR.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.